Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10821988 | 0.84 | OPRM1 (0.42) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL30575153 | 0.78 | TSHR (0.37) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL10821764 | 0.76 | — | — | |
| SCHEMBL7569413 | 0.74 | HMGCR (0.40) | LMNADNM1 | |
| SCHEMBL5517525 | 0.74 | HMGCR (0.40) | LMNADNM1 | |
| SCHEMBL6775172 | 0.74 | HMGCR (0.40) | LMNADNM1 | |
| SCHEMBL4195332 | 0.74 | HMGCR (0.40) | LMNADNM1 | |
| SCHEMBL15846767 | 0.72 | LMNA (0.42) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL15846964 | 0.72 | LMNA (0.42) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL324656 | 0.72 | LMNA (0.42) | LMNADNM1TSHRTHRBOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337266-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Genentech, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3736291-B1 | ANTI-FCRH5 ANTIBODIES | GENENTECH INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230099756-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | GENENTECH, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-20220162318-A1 | Anti-B7-H4 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3917933-A1 | DUOCARMYCIN ANALOGUES | Auckland Uniservices Limited (NZ) | 2021-12-08 | — | — | EP | disclosed |
| US-20210346352-A1 | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| EP-3858387-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seagen Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210115141-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | GENENTECH, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3782654-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3736291-A1 | ANTI-FCRH5 ANTIBODIES | Genentech, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2006028963-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006026747-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1603864-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005070457-A1 | MELPHALAN PRODRUGS | SEATTLE GENETICS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| EP-1476141-A2 | TAMPER-RESISTANT TRANSDERMAL OPIOID DELIVERY DEVICES | Euro-Celtique, S.A. (LU) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004078144-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040033253-A1 | Acyl opioid antagonists | PURDUE PHARMA L.P. | 2004-02-19 | — | — | US | disclosed |
| WO-2003070191-A2 | TAMPER-RESISTANT TRANSDERMAL OPIOID DELIVERY DEVICES | EURO-CELTIQUE, S.A. (LU) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033253-A1 | Acyl opioid antagonists | OPRL1, OGFR, OPRK1 | LMNA 4658/4885DNM1 3362/4885TSHR 1542/4885 |
| US-20230099756-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | CD79B, CD99, BCL6 | LMNA 2638/4885DNM1 829/4885TSHR 1824/4885 |
| US-20210346352-A1 | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES | CD79B, CD99, BCL6 | LMNA 2245/4885DNM1 566/4885TSHR 1148/4885 |
| US-20220162318-A1 | Anti-B7-H4 Antibodies and Immunoconjugates | CD44, NECTIN4, H1-4 | LMNA 4189/4885DNM1 2032/4885TSHR 1741/4885 |
| US-20210115141-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | CD79B, CD99, BCL9 | LMNA 4106/4885DNM1 458/4885TSHR 2554/4885 |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | LMNA 2114/4885DNM1 3831/4885TSHR 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.